Publicaciones en las que colabora con Delvys Rodríguez Abreu (10)

2024

  1. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

    Journal of Thoracic Oncology, Vol. 19, Núm. 8, pp. 1228-1241

2023

  1. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

2022

  1. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)

    Lung Cancer, Vol. 166, pp. 107-113

2021

  1. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

    Journal of Thoracic Oncology

  2. Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression: A network meta-analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 7

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2018

  1. 30 Immunotherapy in advanced NSCLC-from the ' tsunami' of therapeutic knowledge to a clinical practice algorithm: Results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)

    ESMO Open, Vol. 3, Núm. 4

2017

  1. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

    New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246